|
|
||||||||
2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy1

* Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263; and
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Scanty information is available about the mechanisms underlying HLA class I Ag abnormalities in malignant cells exposed to strong T cell-mediated selective pressure. In this study, we have characterized the molecular defects underlying HLA class I Ag loss in five melanoma cell lines derived from recurrent metastases following initial clinical responses to T cell-based immunotherapy. Point mutations in the translation initiation codon (ATG
ATA) and in codon 31 (TCA
TGA) of the
2-microglobulin (
2m) gene were identified in the melanoma cell lines 1074MEL and 1174MEL, respectively. A hot-spot CT dinucleotide deletion within codon 1315 was found in the melanoma cell lines 1106MEL, 1180MEL, and 1259MEL. Reconstitution of
2m expression restored HLA class I Ag expression in the five melanoma cell lines; however, the HLA-A and HLA-B,-C gene products were differentially expressed by 1074MEL, 1106MEL, and 1259MEL cells. In addition, in 1259MEL cells, the Ag-processing machinery components calnexin, calreticulin, and low m.w. polypeptide 10 are down-regulated, and HLA-A2 Ags are selectively lost because of a single cytosine deletion in the HLA-A2 gene exon 4. Our results in conjunction with those in the literature suggest the emergence of a preferential
2m gene mutation in melanoma cells following strong T cell-mediated immune selection. Furthermore, the presence of multiple HLA class I Ag defects within a tumor cell population may reflect the accumulation of multiple escape mechanisms developed by melanoma cells to avoid distinct sequential T cell-mediated selective events.
This article has been cited by other articles:
![]() |
J. M. Kirkwood, A. A. Tarhini, M. C. Panelli, S. J. Moschos, H. M. Zarour, L. H. Butterfield, and H. J. Gogas Next Generation of Immunotherapy for Melanoma J. Clin. Oncol., July 10, 2008; 26(20): 3445 - 3455. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Chang, T. Ogino, D. W. Mullins, J. L. Oliver, G. V. Yamshchikov, N. Bandoh, C. L. Slingluff Jr., and S. Ferrone Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel beta2-Microglobulin Loss-of-function in Melanoma Cells J. Biol. Chem., July 7, 2006; 281(27): 18763 - 18773. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Chen, T. Uno, and B. R. Ksander Tumor Escape Mutants Develop within an Immune-Privileged Environment in the Absence of T Cell Selection J. Immunol., July 1, 2006; 177(1): 162 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Norell, M. Carlsten, T. Ohlum, K.-J. Malmberg, G. Masucci, K. Schedvins, W. Altermann, D. Handke, D. Atkins, B. Seliger, et al. Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity. Cancer Res., June 15, 2006; 66(12): 6387 - 6394. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Purbhoo, D. H. Sutton, J. E. Brewer, R. E. Mullings, M. E. Hill, T. M. Mahon, J. Karbach, E. Jager, B. J. Cameron, N. Lissin, et al. Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors. J. Immunol., June 15, 2006; 176(12): 7308 - 7316. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Paschen, N. Arens, A. Sucker, K. M. Greulich-Bode, E. Fonsatti, A. Gloghini, S. Striegel, N. Schwinn, A. Carbone, R. Hildenbrand, et al. The Coincidence of Chromosome 15 Aberrations and {beta}2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma. Clin. Cancer Res., June 1, 2006; 12(11): 3297 - 3305. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Liu, S. A. Caldwell, K. M. Greeneltch, D. Yang, and S. I. Abrams CTL Adoptive Immunotherapy Concurrently Mediates Tumor Regression and Tumor Escape J. Immunol., March 15, 2006; 176(6): 3374 - 3382. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |